Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Revimid granted fast track designation for relapsed or refractory multiple myeloma

Feb. 6, 2003

ALVAC-CEA/B7.1 under investigation in two colorectal cancer trials

Feb. 4, 2003

Recent developments at Seattle Genetics

Feb. 4, 2003

Phase I results for trastuzumab with IL-2 in nonhematological cancer

Feb. 4, 2003

AlphaRx acquires exclusive rights to VT-1

Jan. 30, 2003

Canvaxin receives fast track designation for metastatic melanoma

Jan. 29, 2003

HuMax-CD4 enters phase II clinical studies for CTCL

Jan. 28, 2003

Rights to cantuzumab mertansine returned to ImmunoGen

Jan. 28, 2003

Single-agent epratuzumab trial closes

Jan. 28, 2003

Pivotal OvaRex trials begin enrollment

Jan. 27, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.